GlaxoSmithKline recalls ANORO ELLIPTA inhalers with failed release testing for coarse particle mass. This may affect inhaler safety and requires checking the NDC code and lot number.
Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification
GlaxoSmithKline is recalling ANORO ELLIPTA inhalers that failed quality testing. This could mean the inhaler doesn't work properly and might not deliver medication safely.
The inhaler failed quality testing for coarse particle mass. This means the medication might not be delivered properly to the lungs, potentially reducing effectiveness.
People with asthma or COPD who use ANORO ELLIPTA inhalers. Those with the specific NDC code 0173-0869-10 and lot number 7Y9S are most at risk.
Check for the NDC code 0173-0869-10 and lot number 7Y9S on the inhaler packaging. The product is a prescription inhaler with 30 doses per unit.
Look for the NDC code 0173-0869-10 and lot number 7Y9S on the inhaler packaging.
The recall is due to failed quality testing, but the inhaler may still be safe to use if it passes the quality check. Check the NDC code and lot number for specifics.
Check for the NDC code 0173-0869-10 and lot number 7Y9S on the inhaler packaging. The product is a prescription inhaler with 30 doses per unit.
The recall does not specify a remedy, so check with your doctor or pharmacist for guidance on whether to continue using the inhaler.
We’ve drafted a message you can send GlaxoSmithKline to request your refund or repair — edit it as you like.
Subject: Recall D-0160-2024 — GlaxoSmithKline GlaxoSmithKline Hello, I own a GlaxoSmithKline that is covered by recall D-0160-2024 from GlaxoSmithKline. I’m writing to arrange the remedy described in the recall (a refund, repair, or replacement as applicable). Could you please tell me the next steps to resolve this? Thank you.
Experiences, tips, and questions from readers. Every comment is reviewed before it appears.
No comments yet — be the first to share your experience.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
